Neuroelectrophysiological effects of Wuqinxi exercise on reactive inhibition deficits in Parkinson's disease.

Psychol Sport ExercMay 16, 2026 (epub)
Clinical ResearchNeurology

Zhen Wang, Yuting Li, Jianing Wei et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the effects of Wuqinxi exercise on motor inhibition deficits in 47 patients with Parkinson's disease. After 24 weeks, participants in the Wuqinxi group showed a significant reduction in interhemispheric inhibition from the right dorsolateral prefrontal cortex to the left primary motor cortex, alongside a decrease in stop signal reaction time.

Key findings

  • Wuqinxi exercise led to a significant reduction in interhemispheric inhibition between the right DLPFC and left M1.
  • Participants demonstrated a pronounced decrease in stop signal reaction time post-intervention.

Why it matters

Understanding the neuroelectrophysiological effects of exercise interventions like Wuqinxi can inform therapeutic strategies for managing motor inhibition deficits in Parkinson's disease, potentially improving patient outcomes.

Source

PubMed · PMID 42142853

Published in Psychol Sport Exerc. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.